Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature.

Details

Ressource 1Download: 37250819_BIB_8E786969EDB9.pdf (1284.14 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_8E786969EDB9
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature.
Journal
SAGE open medical case reports
Author(s)
Liapi A., Atat C., Dunet V., Sarivalasis A.
ISSN
2050-313X (Print)
ISSN-L
2050-313X
Publication state
Published
Issued date
2023
Peer-reviewed
Oui
Volume
11
Pages
2050313X231176401
Language
english
Notes
Publication types: Case Reports
Publication Status: epublish
Abstract
Posterior reversible encephalopathy syndrome is a rare neurological disorder, the diagnosis of which is based on the combination of clinical and radiological findings. It can be associated with many patient-related conditions such as autoimmune disorders or can be provoked by toxins or medication. We report the case of a 70-year-old patient, known for International Federation of Gynecology and Obstetrics stage IVB, high-grade serous ovarian carcinoma, who was diagnosed with a posterior reversible encephalopathy syndrome while on bevacizumab and olaparib maintenance treatment.
Keywords
Posterior reversible encephalopathy syndrome (PRES), bevacizumab, olaparib, ovarian cancer
Pubmed
Web of science
Open Access
Yes
Create date
05/06/2023 9:13
Last modification date
25/01/2024 8:40
Usage data